Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin

Launched by CELLTRION · Jul 23, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether adding a medicine called empagliflozin can help people with type 2 diabetes better control their blood sugar levels. These participants are already taking two other diabetes medicines, metformin and alogliptin, but their blood sugar is still not well controlled. The study aims to find out if empagliflozin is both effective and safe when used alongside these medicines.

Adults diagnosed with type 2 diabetes who are currently taking metformin and alogliptin but still have trouble managing their blood sugar may be eligible to join. Participants will need to agree to take part voluntarily after learning about the study. The trial is open to adults of all genders. People with other types of diabetes, severe uncontrolled diabetes complications, or allergies to the study medicines would not qualify. If you join, you can expect to receive the added medication and be closely monitored to see how well it works and if there are any side effects. This study is currently looking for volunteers to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults at the time of signing the Informed Consent Form (ICF)
• • Signed the written ICF voluntarily after being fully informed of the objectives, methods, and effects of the study
• • Diagnosed with T2DM
• Exclusion Criteria:
• • Diagnosed with other types of diabetes than T2DM
• • History of hypersensitivity reaction to the components or drugs of the same class as the IP or the background therapy
• • Uncontrolled severe complications of diabetes